Contract Animal Testing Sees Potential Growth
This article was originally published in PharmAsia News
The world's life sciences and medical contract research market is expected to hit $21 billion by 2008. China contributed to only 0.5 percent of the global business in 2005, but analysts are positive about the potential of such outsourcing shifting to China and India. In particular, the laboratory animal science industry in the former is forecast to undergo robust growth due to the demand locally and internationally. Thanks to as much as 10 times lower costs, the absence of animal rights activities and standards complying with international requirements, the industry is taking off in a big way. Last year, Shanghai invested 180 million yuan ($25 million) in the biggest laboratory animal production facility in China. (Click here for more - Chinese language)
You may also be interested in...
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.
Wholesalers are given three more years to set up electronic systems to verify saleable returns under another reprieve from the FDA. Yet the reprieve does not extend to manufacturers, who must respond within 24 hours to wholesalers’ requests to manually verify that a returned product is not suspect.
Agency explains how it will model vaccine authorization process on its licensing process for matters like inspections and lot release.